中证智能财讯 华检医疗（01931）4月30日披露2024年度报告。报告期内，公司实现营业总收入31.84亿元，同比增长2.14%；归母净利润2.6亿元，同比增长 9.35%；经营活动产生的现金流量净额为1.4亿元，同比下降52.03%；据报告显示，华检医疗基本每股收益为0.1742元，加权平均净资产收益率为7.3%。 以4月30日收盘价计算，华检医疗目前市盈率（TTM）约10.12倍，市净率（TTM）约0.71倍，市销率（TTM）约0.83倍。 市盈率(TTM)历史分位(%) 001 900 91-24 87c56 80 78:29 70 6645 60 57,98 50 50-99 40 30 20 -20-82 11692 10 0 2019-12-37 1 1-12-37 2n- 制图数据来自恒生聚源数据库 市净率(LF)历史分位(%) (100 90 92g35 86.53 85-21 80 75079 70 60 50 49.6 ad 40 30 29o73 20 1967 10 0 2019-12-37 I 1-12-37 2n- 制图数据来自恒生聚源数据库 华检医疗控股有限公司是一家投资控股公 ...

IVD MEDICAL HOLDING LIMITED 華 檢 醫 療 控 股 有 限 公 司 股份代號 : 1931 (於開曼群島註冊成立的有限公司 ) 何鞠誠先生 （董事會主席兼行政總裁） 林賢雅先生 陳兆基先生 （自二零二四年三月二十八日任命生效） 羅劍輝先生 （自二零二四年三月二十八日任命生效） 非執行董事 姚海雲女士 劉飛先生 （自二零二四年三月八日任命生效） 2O24 年 度 報 告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 主席報告 | 5 | | 管理層討論及分析 | 10 | | 董事及高級管理層 | 31 | | 董事會報告 | 38 | | 企業管治報告 | 65 | | 獨立核數師報告 | 82 | | 綜合損益及其他全面收益表 | 87 | | 綜合財務狀況表 | 89 | | 綜合權益變動表 | 91 | | 綜合現金流量表 | 93 | | 綜合財務報表附註 | 95 | | 五年財務概要 | 180 | 華檢醫療控股有限公司 年度報告 2024 2 公司資料 董事 執行董事 獨立非執行董事 仲人前博士 梁嘉聲博士 黃思樂博士 （自 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 截至二零二四年十二月三十一日止年度業績公告 及恢復買賣 華檢醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈，本公 司及其附屬公司（統稱「本集團」）截至二零二四年十二月三十一日止年度（「報告 期間」）之財務業績如下。 財務摘要 二零二四年 二零二三年 變動 人民幣千元 人民幣千元 | 收益 | 3,162,415 | 3,088,387 | 2.4% | | --- | --- | --- | --- | | 毛利 | 751,173 | 671,701 | 11.8% | | 年內溢利 | 266,034 | 237,126 | 12.2% | | 母公司擁有人應佔溢利 | 260,420 | 23 ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 1,353,470,000, a decrease of 1.7% compared to RMB 1,377,314,000 in the same period of 2023[5] - The gross profit for the same period increased by 7.7% to RMB 324,692,000, up from RMB 301,540,000 in 2023[5] - The net profit for the period rose by 22.7% to RMB 127,566,000, compared to RMB 104,002,000 in the previous year[6] - Profit attributable to equity holders of the parent increased by 21.6% to RMB 125,288,000 from RMB 103,009,000[5] - The adjusted profit for the period, a non-GAAP measure, was RMB 127,790,000, reflecting an 8.9% increase from RMB 117,396,000 in 2023[6] - Basic and diluted earnings per share for the period were RMB 9.27, up from RMB 7.62, representing an increase of 1.65[5] - The company reported an operating loss of RMB 5,012,000 from its proprietary brand product business, which is still in the early research stage, but this loss did not significantly impact overall financial performance[11] - The gross profit margin improved to 24.0%, up by 2.1 percentage points from 21.9% in the previous year[18] - The net profit for the reporting period was RMB 127,566,000, a 22.7% increase from RMB 104,002,000 for the six months ended June 30, 2023, mainly due to the increase in after-sales service gross profit margin[39] - The adjusted net profit for the reporting period was RMB 127,790,000, an increase of 8.9% from RMB 117,396,000 in the previous period, also driven by the increase in after-sales service gross profit margin[40] Revenue Breakdown - Distribution business revenue was RMB 1,253,634,000, accounting for 92.7% of total revenue, down 3.0% from RMB 1,293,002,000[22] - Revenue from solution services provided to clinical laboratories in hospitals reached RMB 117,462,000, a 4.7% increase from RMB 112,227,000 for the six months ended June 30, 2023[9] - Revenue from the sale of medical consumables was RMB 1,170,596,000, an increase of 1.2% from RMB 1,156,622,000 in the previous year[83] - Revenue from after-sales services increased significantly to RMB 95,258,000, up 22% from RMB 78,163,000 in the prior year[83] - Revenue from sales to hospitals and medical institutions was RMB 188,124,000, an increase from RMB 171,061,000 in the previous year[83] Market Position and Strategy - The company is a leading distributor of IVD products in China and is involved in the research, development, production, and sales of its own brand IVD products[7] - The company aims to stabilize and increase market share and profitability through a competitive and diversified product portfolio and extensive distribution network[7] - The company continues to focus on expanding its market presence and enhancing its product offerings in the IVD sector[7] - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market[14] - The company aims to enhance its R&D capabilities by investing in equipment and hiring experts to develop proprietary IVD products[16] Assets and Liabilities - Cash and cash equivalents increased by 29.8% to RMB 1,589,593,000 compared to RMB 1,224,786,000 at the end of 2023[19] - The total assets of the company rose by 11.3% to RMB 5,328,067,000 from RMB 4,785,052,000[19] - The net current assets increased to RMB 1,829,422,000 as of June 30, 2024, compared to RMB 1,783,091,000 as of December 31, 2023, reflecting an increase of RMB 46,331,000[45] - The group's debt-to-asset ratio was approximately 15.0% as of June 30, 2024, significantly up from 6.7% as of December 31, 2023[54] - The total liabilities as of June 30, 2024, were RMB 259,617,000, a decrease from RMB 330,790,000 as of December 31, 2023, reflecting a reduction of approximately 21.5%[95] Shareholder Information - The total issued and paid-up share capital is 1,354,590,080 shares, with a par value of USD 0.0005 per share, equivalent to RMB 4,637,000[97] - The company has a total of 175,517,429 shares held by KS&KL Investment Co. Limited, representing 12.96% of the issued shares[106] - The company’s major shareholder, King Sun Limited, also holds 175,517,429 shares, accounting for 12.96% of the issued shares[108] - The total shares held by the directors and major executives amount to 465,185,899 shares collectively[107] - The company’s shareholding structure indicates significant control by a few major shareholders, which may impact future strategic decisions[108] Employee Stock Option Plan - The employee stock option plan allows for the issuance of up to 32,507,627 shares, representing 5% of the total issued shares at the time, aimed at attracting and retaining top talent[117] - The management of the employee stock option plan is vested in the board or a committee authorized by the board, ensuring compliance with applicable laws and company regulations[118] - The total number of unexercised stock options as of the interim report date is 19,504,576, representing approximately 0.96% of the total issued shares[128] - The stock option plan is effective for ten years from July 12, 2019, unless terminated earlier by the shareholders or the board[132] - The employee stock option plan is designed to reward employees and promote the overall success of the group, aligning employee interests with company performance[116] Corporate Governance - The company has complied with all applicable corporate governance code provisions except for the separation of the roles of Chairman and CEO[146] - The audit committee reviewed the interim report and found the financial statements to be prepared in accordance with applicable accounting standards[148] - The board composition has changed with several new appointments and resignations during the reporting period[151][152] - The company has adopted a standard code for securities transactions by directors, and all directors confirmed compliance during the reporting period[145] Future Outlook - The Chinese IVD market is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[12] - The company is actively exploring business cooperation opportunities, including technology exchanges, to enhance its market competitiveness[16] - The company signed a strategic cooperation agreement with Sysmex in 2023 to deepen collaboration and revise distribution rights, transitioning to long-term distribution rights in specific regions[8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 截至二零二四年六月三十日止六個月之 中期業績公告 財務摘要 華檢醫療控股有限公司（「本公司」）董事（「董事」，各自為「董事」）會（「董事會」） 謹此宣佈本公司及其附屬公司（此後統稱「本集團」）截至二零二四年六月三十日止 六個月（「報告期間」）的未經審核綜合中期業績，其已經本公司審核委員會（「審核 委員會」）審閱及已經董事會於二零二四年八月二十八日核准。本集團於報告期間 的財務摘要連同二零二三年同期的比較數字載列如下： | --- | --- | --- | |---------------------------|-----------------------------------|--------| | 二零二四年 | 截至六月三十日止六個月 二零二三年 | 變動 ...

Financial Performance - The company recorded revenue of RMB 3,088,387,000 in 2023, a year-on-year increase of 12.4%, with net profit growing by 21.3% to RMB 237,126,000[3] - Revenue for the reporting period reached RMB 3,088,387,000, a 12.4% increase compared to RMB 2,748,809,000 in 2022, driven by increased demand for IVD products as hospital operations normalized post-COVID-19[36] - Net profit for the year was RMB 237,126,000, a 21.3% increase from RMB 195,530,000 in 2022, with profit attributable to owners of the parent company rising 13.4% to RMB 238,163,000[25] - Adjusted net profit under non-GAAP measures increased by 17.0% to RMB 262,124,000, compared to RMB 224,052,000 in 2022[25] - The company's revenue for 2023 reached RMB 3,088,387,000, a 12.4% increase compared to 2022[80] - Net profit for 2023 grew by 21.3% to RMB 237,126,000, driven by increased revenue and reduced expenses[80] - Adjusted profit for the year reached RMB 262,124,000, a 17.0% increase compared to the previous year[61] Gross Profit and Margins - The company's gross profit in 2023 was RMB 671,701,000, a year-on-year increase of 10.5%[18] - Gross profit margin decreased slightly by 0.4 percentage points to 21.7%, while net profit margin improved by 0.6 percentage points to 7.7%[32] - The company's gross profit increased by 10.5% to RMB 671,701,000 in 2023[80] EBITDA and Adjusted Net Profit - EBITDA in 2023 was RMB 397,928,000, a year-on-year increase of 13.8%[18] - The company's adjusted net profit in 2023 was RMB 262,124,000, a year-on-year increase of 17.0%[18] Product and Market Performance - As of December 31, 2023, the company had installed and put into use 6,920 Sysmex coagulation analyzers in hospitals and medical institutions[1][4] - The company's solution services generated revenue of RMB 241,944,000 in 2023, an increase of 17.8% compared to RMB 205,406,000 in 2022[13] - The company provided solution services to seven top-tier hospitals in China in 2023[13] - The company holds a 43.2% market share in the Chinese coagulation analysis IVD primary distribution market, with a penetration rate of 74.0% in the top 100 hospitals[19] - Sales through distributors to hospitals and medical institutions grew by 8.5% to RMB 2,355,731,000, accounting for 80.9% of total sales[22] - Sales of self-branded products surged by 69.8% to RMB 10,623,000, with sales to hospitals and medical institutions increasing by 581.7% to RMB 1,493,000[22] - Distribution business revenue accounted for 93.9% of total revenue, amounting to RMB 2,898,390,000, with a year-on-year growth of 12.5%[37] - After-sales service revenue grew by 7.3% to RMB 179,374,000, representing 5.8% of total revenue[37] - Own-brand product revenue surged by 69.8% to RMB 10,623,000, contributing 0.3% to total revenue[37] - The IVD reagent and consumables segment under the distribution business grew by 15.9% to RMB 2,567,873,000, accounting for 88.3% of the distribution business revenue[52] - Own-brand IVD reagent and consumables revenue increased significantly by 89.3% to RMB 8,755,000[52] - The company installed 106 Sysmex coagulation immunoassay analyzers in Chinese hospitals and medical institutions by the end of 2023, expanding its product portfolio with 4 types of thrombus markers[62] - The Chinese coagulation analysis IVD market size reached RMB 5 billion in 2021, with the top three market participants holding a cumulative market share of 77.7%[38] - The company's product portfolio now includes over 500 products from 20 local IVD manufacturers and 6 foreign IVD manufacturers[64][68] - Solution services revenue increased by 17.8% to RMB 241,944,000 in 2023, serving seven top-tier hospitals in China[77] R&D and Strategic Expansion - The company plans to expand its product portfolio and distribution network, and increase hospital coverage[7] - The company aims to enhance its R&D capabilities through organic growth and acquisitions[9] - The company plans to expand its R&D capabilities in 2024, focusing on mass spectrometry reagents, microbiology analyzers, and molecular diagnostics[65] - The company's "Huajian Ecosystem" project has been expanded to cover all major product categories, with a focus on instant testing and precision diagnostics[64][87] - The company has acquired two local IVD R&D companies with expertise in mass spectrometry and microbial sample preprocessing[69] - The company's strategic partnership with Sysmex has been renewed, with Sysmex increasing its investment in the company's subsidiary[70][84] Financial Position and Capital - Total assets increased by 10.9% to RMB 4,785,052,000, with cash and cash equivalents rising by 20.0% to RMB 1,224,786,000[32] - The average turnover days for trade receivables decreased by 9 days to 65 days, while inventory turnover days increased by 20 days to 131 days[32] - The company's return on equity (ROE) improved by 0.5 percentage points to 7.3%, and return on assets (ROA) increased by 0.7 percentage points to 5.2%[32] - The company's total capital expenditure during the reporting period was approximately RMB 40,508,000, mainly used for the purchase of property, plant, and equipment[122] - The company did not hold any significant equity investments in other companies as of December 31, 2023[109] - The company did not have any significant contingent liabilities, guarantees, or litigation as of December 31, 2023[108] - The company focuses on maintaining a balance between funding continuity and flexibility through bank borrowings and expected operating cash flows[102] - The company has a nationwide distribution network and employs strict guidelines for selecting, evaluating, and monitoring distributors[119] - The company did not use any interest rate swaps to hedge its interest rate risk as of December 31, 2023[101] - The company recorded a net foreign exchange gain of RMB 9.2 million during the reporting period, compared to a net foreign exchange loss of RMB 10.335 million in the previous year[126] - The company's asset-to-liability ratio was approximately 6.7% as of December 31, 2023, down from 7.6% in the previous year[128] - The company made a capital commitment of RMB 29.829 million to a joint venture as of December 31, 2023, slightly lower than RMB 30.401 million in the previous year[129] - The net proceeds from the company's initial public offering were approximately HKD 902.9 million, with a remaining balance of HKD 1.3 million at the beginning of the reporting period allocated for continued R&D of proprietary products[132] - The recoverable amount of the allocated cash-generating unit exceeded its carrying amount by no less than RMB 100 million, based on a five-year financial budget forecast[126] Dividends and Shareholder Returns - The company declared a final dividend of RMB 76,314,000, equivalent to 6.209 HK cents per share[74] - The company declared a final dividend of HK$0.06209 per share for the reporting period, with a total of approximately RMB 76,314,000 to be paid from the share premium account[161] - The company's share premium account balance as of December 31, 2023, was approximately RMB 2,224,295,000, and after the final dividend payment, the remaining balance will be approximately RMB 2,147,981,000[161] - The company declared an interim dividend of HK$0.0297 per share for the six months ended June 30, 2023, totaling approximately RMB 36,935,000[178] Corporate Governance and Board - The company's board of directors is committed to achieving a high level of corporate governance[190] - The company's board of directors has adopted the standard code set out in Appendix C3 of the Listing Rules for securities transactions by directors, and all directors have confirmed compliance during the reporting period[191] - The company's board of directors has implemented a share incentive plan, with details provided in the board report section on "Share Plans"[183] - The board consists of 8 members, with 1 being female, ensuring gender diversity and diverse perspectives[194] - The board maintains at least one female representative to ensure balanced gender representation[194] - No reward shares were granted or issued during the reporting period[200] - The audit committee is responsible for reviewing and monitoring financial reporting, risk management, and internal control standards, meeting at least twice a year[199] Employees and Compensation - The company employed 803 staff as of December 31, 2023, an increase from 755 in the previous year, with total employee compensation (including directors' remuneration) amounting to RMB 183.869 million[130] - The company's mandatory provident fund (MPF) plan for Hong Kong employees is a defined contribution retirement benefit scheme, with contributions based on a percentage of employees' basic salaries[157] - The company's senior management's annual compensation ranges were disclosed during the reporting period, though specific figures were not provided[156] Market and Competition - The IVD market in China is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[21] - The company may face intense competition due to government policies encouraging large distributors to expand through acquisitions of smaller distributors[174] Partnerships and Relationships - The company maintained long-term partnerships with multiple suppliers, ensuring compliance with quality and ethical standards[139] - The company's major customers include distributors, hospitals, medical institutions, and logistics providers, with a focus on superior customer service to enhance profitability[148] - The company has maintained close relationships with several well-known hospitals through its Chinese subsidiaries[187] - The company signed a strategic cooperation agreement with Sysmex Medical Electronics (Shanghai) Co., Ltd., revising the distribution rights to long-term distribution rights and receiving an equity investment from Sysmex[160] Share Capital and Issuance - The company's issued share capital as of December 31, 2023, was 1,500,000 USD, divided into 3,000,000,000 shares of 0.0005 USD each[181] - No unvested reward shares as of December 31, 2023[92] - The company did not grant or will grant options and rewards exceeding 1% of the total issued shares[93] Credit and Risk Management - Expected credit losses are recognized in two stages: 12-month expected credit losses for exposures without significant credit risk increase, and lifetime expected credit losses for exposures with significant credit risk increase[95] - The company uses a simplified method to calculate expected credit losses for trade receivables without significant financing components, based on historical credit loss experience and forward-looking factors[96]

截至二零二三年十二月三十一日止年度業績公告 1 綜合損益及其他全面收益表 截至二零二三年十二月三十一日止年度 | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------|-------|-------------------|------------------| | | | | | | 換算國外業務產生之匯兌差額 註銷一間附屬公司時變現之匯兌波動儲備 | | 781 1,691 | (5,198) – | | | | 2,472 | (5,198) | | 將不會於後續期間重新歸類為損益之 其他全面（虧損）╱收益： 本公司財務報表換算產生的匯兌差額 | | (2,405) | 47,283 | | 年內其他全面收益，扣除稅項 | | 67 | 42,085 | | 年內全面收益總額 | | 237,193 | 237,615 | | | | | | | 應佔全面收益總額： | | | | | 母公司擁有人 非控股權益 | | 238 ...

管理層討論及分析（續） 收益 於報告期間，本集團的收益為人民幣1,377,314,000元，較截至二零二二年六月三十日 止六個月的人民幣1,176,557,000元增加17.1%。有關增加主要是由於終端客戶對IVD產 品的需求增加，這是由於於報告期間，醫院的營運在COVID-19過後逐步恢復正常。 按業務分部劃分的收益 下表載列於所示期間本集團按業務分部劃分的收益明細： 截至六月三十日止六個月 | --- | --- | --- | --- | --- | --- | |------------------|-----------------------|-------|-----------------------|-------|--------| | 業務分部 | 二零二三年 人民幣千元 | % | 二零二二年 人民幣千元 | % | 變動 | | | | | | | | | | | | | | | | 分銷業務 | 1,293,002 | 93.9 | 1,097,468 | 93.2 | 17.8% | | 售後服務 | 78,163 | 5.7 | 77,286 | 6.6 | 1.1% | | ...

財務摘要 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 華檢醫療控股有限公司（「本公司」）董事（「董事」，各自為「董事」）會（「董事會」） 謹此宣佈本公司及其附屬公司（此後統稱「本集團」）截至二零二三年六月三十日止 六個月（「報告期間」）的未經審核綜合中期業績，其已經本公司審核委員會（「審核 委員會」）審閱及已經董事會於二零二三年八月十八日核准。本集團於報告期間的 財務摘要連同二零二二年同期的比較數字載列如下： 收益 毛利 期內溢利 母公司擁有人應佔溢利 期內經調整溢利 （非公認會計原則，見附註） 母公司擁有人應佔經調整溢利 （非公認會計原則，見附註） 每股盈利 基本（人民幣分） 攤薄（人民幣分） 於報告期間，本集團實現收益人民幣1,377,314,000元，較二零二二年同期增加 17.1%。有關增加主要是由於終端客戶對體外診斷（「IVD」）產品的需求增加，這 是由於醫院的營運在新型冠狀病毒疫情（「COVID-19」）過後逐步恢復正常。 附註：期內經調整溢利及母公司擁有人應佔經調整溢利為非公認會計原則財務計量，並按期內 ...

Business Expansion and Market Presence - The company has expanded its product portfolio under the "Hua Jian Ecosystem" project to cover over 500 products from 18 local IVD manufacturers and 6 foreign manufacturers[15]. - As of December 31, 2022, the company had 295 direct customers and 1,139 distributors, covering 1,599 tertiary hospitals in China[25]. - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[29]. - The company aims to expand its distribution network and hospital coverage as part of its business strategy in China[30]. - The company is expanding its market presence in D regions, aiming to capture E% of the market share by the end of the next fiscal year[74]. - The company aims to provide solutions for at least two new hospitals in 2023 to capitalize on market trends and opportunities[130]. - The product portfolio includes over 500 products from 18 local IVD manufacturers with independent intellectual property rights and 6 well-known foreign IVD manufacturers[128]. - The company has established strategic partnerships with renowned IVD manufacturers to enhance its product offerings and expand its distribution network[128]. Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[74]. - The group achieved revenue of RMB 2,748,809,000, representing a growth of 0.7% compared to the previous year[159]. - The company reported revenue of RMB 2,748,809,000 for the year ended December 31, 2022, an increase of 0.7% compared to RMB 2,730,670,000 in 2021[180]. - Net profit for the year increased by 20.9% to RMB 195,530,000, driven by an increase in gross margin and a reduction in employee compensation expenses related to the share incentive plan[181]. - Adjusted net profit for the year was RMB 224,052,000, representing a growth of 12.0% compared to RMB 200,048,000 in the previous year[186]. - The adjusted net profit attributable to the company's shareholders rose by 11.1% to RMB 228,504,000 from RMB 205,706,000 in 2021[186]. - Basic earnings per share increased to RMB 15.61 from RMB 13.19, while diluted earnings per share rose to RMB 15.50 from RMB 12.94[180]. - The board proposed a final dividend of RMB 66,206,000, equating to HKD 0.05556 per share, in recognition of the support from shareholders[35]. - The company proposed a final dividend of HKD 0.05556 per share for the year ended December 31, 2022[182]. Research and Development - The company plans to enhance its R&D capabilities through internal growth and acquisitions, focusing on mass spectrometry and microbiology analysis[34]. - Research and development expenditures increased by H%, reflecting the company's commitment to innovation and product development[74]. - The company has been actively seeking investment opportunities in high-tech and innovative local IVD manufacturers to expand its ecosystem[15]. Environmental Sustainability - The company aims to enhance its environmental sustainability by implementing energy-saving measures and reducing greenhouse gas emissions[184]. - The total greenhouse gas emissions (Scope 1 and 2) amounted to 965.93 tons of CO2 equivalent, an increase from 858.35 tons in the previous year[164]. - Direct greenhouse gas emissions (Scope 1) increased to 620.22 tons of CO2 equivalent from 526.45 tons in the previous year[164]. - Energy indirect greenhouse gas emissions (Scope 2) were reported at 345.71 tons of CO2 equivalent, up from 331.90 tons in the previous year[164]. - The total amount of harmless waste per million RMB of revenue decreased by approximately 50% compared to the previous year, reflecting improved employee awareness of waste reduction[192]. - Energy consumption density increased by approximately 2.17% compared to the previous year, primarily due to the recovery of business activities involving vehicle usage[198]. - The group is actively seeking opportunities to implement environmental measures to improve its environmental performance[156]. - The group has established internal control mechanisms to enhance environmental awareness among employees and comply with relevant laws and regulations[156]. Corporate Governance - The Group has complied with all disclosure requirements under the Listing Rules regarding related party transactions[45]. - The Board of Directors has confirmed compliance with the corporate governance code throughout the reporting period[55]. - The Group's audit committee reviewed the unaudited interim financial statements for the six months ending June 30, 2022[70]. - The audit committee is responsible for reviewing the Group's financial information and discussing accounting policies and practices with management and external auditors[71]. - The Group has established four board committees to oversee specific areas of governance[66]. - The Group's non-executive directors serve a term of three years, with the possibility of reappointment[61]. - The Group has implemented a framework for high-level corporate governance to protect shareholder interests and enhance corporate value[54]. - The Group has engaged Ernst & Young as its auditor to report on related party transactions in accordance with the Listing Rules[45]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, targeting a G% reduction in costs over the next year[74]. - Employee compensation expenses related to the share incentive plan decreased significantly from RMB 38,555,000 in 2021 to RMB 11,993,000 in the reporting period[181]. - The Group paid approximately RMB 3,664,000 in actual rent to the Xinhua Medical Group during the reporting period for properties leased in Shanghai and Jinan[43]. - The rental agreements are short-term leases with a duration not exceeding one year, involving fixed amounts plus utilities and management fees[43].